Systemic and Ocular Determinants of Peripapillary Retinal Nerve Fiber Layer Thickness Measurements in the European Eye Epidemiology (E3) Population

Citation for published version (APA):

Mauschitz, M. M., Bonnemaier, P. W. M., Diers, K., Rauscher, F. G., Elze, T., Engel, C., Loeffler, M., Colijn, J. M., Ikram, M. A., Vingerling, J. R., Williams, K. M., Hammond, C. J., Creuzot-Garcher, C., Bron, A. M., Silva, R., Nunes, S., Delcourt, C., Cougnard-Gregoire, A., Holz, F. G., ... Berendschot, T. (2018). Systemic and Ocular Determinants of Peripapillary Retinal Nerve Fiber Layer Thickness Measurements in the European Eye Epidemiology (E3) Population. *Ophthalmology*, 125(10), 1526-1536. <https://doi.org/10.1016/j.ophtha.2018.03.026>

Document status and date:

Published: 01/10/2018

DOI:

[10.1016/j.ophtha.2018.03.026](https://doi.org/10.1016/j.ophtha.2018.03.026)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Download date: 26 Apr. 2023

Systemic and Ocular Determinants of Peripapillary Retinal Nerve Fiber Layer Thickness Measurements in the European Eye Epidemiology (E3) Population

Matthias M. Mauschitz, MD,^{1,2} Pieter W.M. Bonnemaier, MD,^{3,4} Kersten Diers, MSc,¹ Franziska G. Rauscher, PhD,^{5,7} Tobias Elze, PhD,^{5,6} Christoph Engel, MD, PhD,^{5,7} Markus Loeffler, MD, PhD,^{5,7} Johanna Maria Colijn, MD, MSc,^{3,4} M. Arfan Ikram, MD, PhD,⁴ Johannes R. Vingerling, MD, PhD,³ Katie M. Williams, MD, PhD,⁸ Christopher J. Hammond, MD, PhD,⁸ Catherine Creuzot-Garcher, MD, PhD,^{9,10} Alain M. Bron, MD, PhD,^{9,10} Rufino Silva, MD, PhD,^{11,12,13} Sandrina Nunes, PhD,¹³ Cécile Delcourt, PhD,¹⁴ Audrey Cougnard-Grégoire, PhD,¹⁴ Frank G. Holz, MD,² Caroline C.W. Klaver, MD, PhD,^{3,4} Monique M.B. Breteler, MD, PhD,^{1,15} Robert P. Finger, MD, PhD,² on behalf of the European Eye Epidemiology (E3) Consortium

Purpose: To investigate systemic and ocular determinants of peripapillary retinal nerve fiber layer thickness (pRNFLT) in the European population.

Design: Cross-sectional meta-analysis.

Participants: A total of 16 084 European adults from 8 cohort studies (mean age range, 56.9±12.3–82.1±4.2 years) of the European Eye Epidemiology (E3) consortium.

Methods: We examined associations with pRNFLT measured by spectral-domain OCT in each study using multivariable linear regression and pooled results using random effects meta-analysis.

Main Outcome Measures: Determinants of pRNFLT.

Results: Mean pRNFLT ranged from 86.8±21.4 µm in the Rotterdam Study I to 104.7±12.5 µm in the Rotterdam Study III. We found the following factors to be associated with reduced pRNFLT: Older age ($\beta = -0.38$ µm/year; 95% confidence interval [CI], -0.57 to -0.18), higher intraocular pressure (IOP) ($\beta = -0.36$ µm/mmHg; 95% CI, -0.56 to -0.15), visual impairment ($\beta = -5.50$ µm; 95% CI, -9.37 to -1.64), and history of systemic hypertension ($\beta = -0.54$ µm; 95% CI, -1.01 to -0.07) and stroke ($\beta = -1.94$ µm; 95% CI, -3.17 to -0.72). A suggestive, albeit nonsignificant, association was observed for dementia ($\beta = -3.11$ µm; 95% CI, -6.22 to 0.01). Higher pRNFLT was associated with more hyperopic spherical equivalent ($\beta = 1.39$ µm/diopter; 95% CI, 1.19 – 1.59) and smoking ($\beta = 1.53$ µm; 95% CI, 1.00 – 2.06 for current smokers compared with never-smokers).

Conclusions: In addition to previously described determinants such as age and refraction, we found that systemic vascular and neurovascular diseases were associated with reduced pRNFLT. These may be of clinical relevance, especially in glaucoma monitoring of patients with newly occurring vascular comorbidities. *Ophthalmology* 2018;125:1526–1536 © 2018 by the American Academy of Ophthalmology

Supplemental material available at www.aajournal.org.

The assessment of peripapillary retinal nerve fiber layer thickness (pRNFLT) with spectral-domain OCT has become of increasing importance in the evaluation of glaucoma and its progression.^{1,2} Although debated, pRNFLT measurements hold promise as a biomarker for neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis.^{3,4}

Although pRNFLT measurements have increased insight into the development of diseases, it has been difficult to evaluate which changes fall within the physiologic range. Most OCT devices compare pRNFLT measurements with reference databases that are built into the machine analysis software. These data are mostly derived from relatively

small sample populations. Whether these databases adequately capture normal anatomic variation across a wide age range remains unclear.

Few studies have investigated ocular and systemic determinants of pRNFLT in the general population.⁵ They reported inconsistent results for many ocular and systemic parameters, including sex and body mass index (BMI).^{5,6} To date, only age,^{7,8} refraction,⁹ and axial length (AL)¹⁰ have been consistently associated with measured pRNFLT across studies. In addition, the majority of large-scale studies assessing these associations were performed in young Asian populations.^{6,11–14} It is unclear whether these

results can be applied to European, that is, mostly white, populations. The purpose of this study was to assess systemic and ocular determinants of pRNFLT using pooled data from 8 European population-based studies.

Methods

Included Studies

The European Eye Epidemiology (E3) consortium is a collaborative network of population-based studies across Europe with the overarching aim of developing and analyzing large pooled datasets to increase understanding of eye disease and vision loss.¹⁵ For this study, we analyzed data on pRNFLT from 8 different studies. The included data were cross-sectional, and the right eye was chosen to be the study eye. All studies adhered to the tenets of the Declaration of Helsinki and had local ethical committee approval. All participants gave written informed consent.

Assessments and Data Analyses

Retinal nerve fiber layer thickness was measured as global pRNFLT with different OCT devices, scan modalities (mostly circular scans), and automated segmentation algorithms in the respective studies (Table 1). The pRNFLT outliers were excluded before analyses according to Chauvenet's criterion.¹⁶ Briefly, depending on sample size, we excluded participants with pRNFLT above or below a certain range of standard deviations from the mean.¹⁶ To investigate the determinants of pRNFLT, multivariable linear regression models including the variables of interest were conducted. Factors to be tested for association with pRNFLT were considered in multiple steps. As the first and most important step, variables were chosen a priori on the basis of literature and availability in the individual studies. Subsequently, we performed univariable linear regression models of potential factors at study level to assess the possible impact on pRNFLT. In the last step, the factors of the multivariable models were decided on as a trade-off between the priority of the respective factors and the maximum possible population size of the model.

The independent variables of the multivariable linear regression model were age, sex, BMI, visual impairment as defined by the World Health Organization (best-corrected visual acuity [BCVA] <0.3 decimal), intraocular pressure (IOP), spherical equivalent (SE), smoking status, and history of systemic hypertension, diabetes, stroke, and dementia. The multivariable regression model was conducted for each individual study, and residuals were then plotted and normal distribution assessed. Because OCT devices were changed within the course of the Rotterdam Study (from 3D-OCT 1000 to 3D-OCT 2000, Topcon Medical Systems, Oakland, NJ), we controlled for the OCT device in the multivariable regression models of the Rotterdam Study II and III. In the TwinsUK Study, we performed a hierarchical multivariable regression model to control for family dependencies between twins (See Study Descriptions and pRNFLT Distributions, available online at www.aaojournal.org).

Subsequently, random-effects meta-analysis was used to combine effect estimates (beta coefficients) of each individual predictor from the multivariable regression models among studies. A random-effects approach was chosen a priori on the basis of the heterogeneity in the data caused by the different OCT devices¹⁷ and the set-up of the studies. Our analyses were conducted twice, with and without patients with known glaucoma.

Not all independent variables of the multivariable regression model were available in every participating study. Therefore, the

multivariable regression models in the respective studies were performed without the missing variables, and the study was excluded from the meta-analysis of that respective missing covariate. All analyses were performed with the statistical software RStudio (R version 3.4.1, RStudio Inc., Boston, MA, <https://www.rstudio.com/>), and statistical significance was set at $P < 0.05$.

Results

A total of 16 084 participants from 8 population-based studies were included; approximately 1% of pRNFLT outliers per study were excluded (Table S1, available at www.aaojournal.org). The mean age of participants ranged from 56.9 ± 12.3 years in the LIFE Study to 82.1 ± 4.2 years in the Alienor Study. Mean global pRNFLT ranged from 86.8 ± 21.4 μm in the Rotterdam Study I to 104.7 ± 12.5 μm in the Rotterdam Study III (Table 1). Further participant characteristics for each study are presented in Table S1 (available at www.aaojournal.org). The results of the multivariable regression models for each individual study are reported in Table 2. Data on dementia were only available in the Rotterdam Study cohorts and the Alienor Study. Furthermore, in the TwinsUK Study, no sufficient data were available on visual impairment, glaucoma, hypertension, and smoking status; in the LIFE Study, no data were available on visual impairment, SE, and IOP.

In the meta-analyzed multivariable regression model (Table 3 and Fig 1A, B), age and IOP were negatively associated with pRNFLT, even after excluding patients with glaucoma. A history of stroke and hypertension were both associated with a reduced pRNFLT. When substituting hypertension with mean systolic blood pressure (in mmHg), no association was found.

A suggestive, but nonsignificant association with reduced pRNFLT was observed for dementia. Visual impairment as defined by the World Health Organization was associated with reduced pRNFLT in the meta-analysis. We found this association in the Alienor and Rotterdam Study I-III, whereas there was no association in the Montrachet and Coimbra Studies.

Women had a thicker pRNFLT than men did in the meta-analysis. However, when correcting for AL rather than SE in the 5 studies with data on AL, this association disappeared. The SE was positively associated with pRNFLT, even after excluding highly myopic eyes (< -6 diopters) and highly hyperopic eyes ($> +4$ diopters), as well as eyes with pseudophakia (Fig S1A, B, available at www.aaojournal.org). Longer AL was associated with reduced pRNFLT in our sensitivity analyses ($\beta = -3.48$ μm per mm longer AL, 95% confidence interval [CI], -4.18 to -2.77) (Fig S1C, available at www.aaojournal.org). Both former and current smoking were associated with thicker pRNFLT, but prevalence and associations differed considerably between studies. To assess the influence of education on smoking, we corrected for education, and the associations persisted. After excluding data from the LIFE Study, which is the largest study with the highest proportion of smokers (data weighted $>60\%$ in the meta-analysis), the association remained significant for current but not for former smoking (Fig S1D–G, available at www.aaojournal.org). For BMI, we found a small but significant association with increased pRNFLT after excluding patients with glaucoma. All associations except for former smoking held true after excluding the 619 patients with known glaucoma (Table 3). Furthermore, we detected no relevant changes of associations when performing the multivariable regression analyses stratified by sex or when excluding the LIFE study cohort being the largest single study (results not reported).

Table 1. Descriptive Data for Participating Studies

Study	Years	City/Country	pRNFLT Measurements		N	Women (%)	Mean Age in Years $\pm$ SD	Mean Global pRNFLT in Microns $\pm$ SD
			OCT Device	Details				
Alienor Study	2009–2011	Bordeaux, France	Spectralis OCT,	12°/3.4-mm diameter	529	62%	82.1 $\pm$ 4.2	89.2 $\pm$ 16.0
Coimbra Eye Study	2016–2017	Coimbra, Portugal	Heidelberg Engineering	ring scan on ONH	618	54%	71.8 $\pm$ 6.2	96.8 $\pm$ 12.0
Montrachet Study	2009–2013	Dijon, France	(Heidelberg, Germany)		803	60%	82.0 $\pm$ 3.7	90.3 $\pm$ 13.7
LIFE Study	2011–2014	Leipzig, Germany			8351	52%	56.9 $\pm$ 12.3	97.4 $\pm$ 10.6
Rotterdam Study I	2009–2011	Rotterdam, The Netherlands	3D OCT 1000, Topcon Medical Systems (Oakland, NJ)	6.0 $\times$ 6.0 mm on ONH	1287	57%	79.3 $\pm$ 4.6	86.8 $\pm$ 21.4
Rotterdam Study II	2011–2012		3D OCT 1000 and 2000, Topcon Medical Systems		1376	55%	72.4 $\pm$ 4.9	98.2 $\pm$ 17.2
Rotterdam Study III	2012–2013		iVue, Optovue (Fremont, Calif)	3.45-mm diameter ring scan on ONH	2267	56%	62.2 $\pm$ 5.6	104.7 $\pm$ 12.5
Twins UK Study	2014–2016	UK (multiple cities)			853	98%	61.8 $\pm$ 12.2	96.4 $\pm$ 9.8

ONH = optic nerve head; pRNFLT = peripapillary retinal nerve fiber layer thickness; SD = standard deviation (See Study Descriptions and pRNFLT Distributions, available online at www.aaojournal.org).

Discussion

Our study confirms the previously reported associations of age and SE with pRNFLT and identifies several additional factors associated with pRNFLT, namely, IOP (even in individuals without a history of glaucoma), stroke, hypertension, and smoking. Furthermore, we found a trend of reduced pRNFLT in participants with dementia. Our results suggest that a number of ocular and systemic factors need to be considered when assessing pRNFLT. To date, none of this has been implemented as potentially influencing factors in reference databases for OCT devices or any algorithms assessing pRNFLT change.

First publications on determinants of OCT-based pRNFLT measurements reported older age and greater AL to be associated with thinner pRNFLT.^{18,19} Budenz et al¹⁹ investigated determinants of pRNFLT in 328 normal subjects aged 18 to 85 years using time-domain OCT and described a decrease of 2.0 μ m pRNFLT per decade and a decrease of 2.2 μ m per mm AL.¹⁹ These estimates are smaller but still are comparable to our results (decrease of 3.8 μ m pRNFLT on average per decade and 3.48 μ m per mm AL). A subsequent study evaluated determinants of pRNFLT in 542 healthy adults aged 40 to 80 years using spectral-domain OCT (Cirrus HD-OCT; Carl Zeiss Meditec, Inc, Dublin, CA) and confirmed the associations of pRNFLT with age and AL.¹¹

Subsequently, larger population studies mostly from Asia were conducted to investigate further determinants of pRNFLT. We have affirmed results from the Beijing Eye Study in 2548 participants considering the influence of age and refractive error. That study also showed a higher pRNFLT of 2.9 μ m in women,¹⁴ in keeping with our results of women having a higher pRNFLT of 2.2 μ m. Similar to our models, the Beijing Eye Study corrected for refractive error instead of actual AL. Of note, after correcting for AL in our analyses, sex was no longer associated with pRNFLT; thus, we hypothesize that AL, which is on average shorter in women, confounds the effect of sex on pRNFLT. In general, SE is a good proxy for AL, and we found a strong association of higher SE with thicker pRNFLT, even in our sensitivity analysis, which eliminated subjects with high refractive errors. The underlying mechanisms of the association of longer AL and thinner pRNFLT are arguable.²⁰ Frequently suggested mechanisms are a stretching due to a longer eye bulb or artificially decreased measurements due to magnification.^{21,22} However, irrespective of the causal mechanism, the clinical relevance of adjusting for refraction or AL in OCT imaging seems obvious.

Higher IOP was associated with reduced pRNFLT in our analyses even after excluding patients with known glaucoma. However, because glaucoma was self-reported in some of the participating studies, not all patients with actual glaucoma might have been excluded in our analyses. Visual impairment (BCVA <0.3 decimal) as a proxy for any ocular pathology was associated with thinner pRNFLT in the Alienor Study and all of the Rotterdam Studies. The Coimbra and Montrachet Studies were likely underpowered to find an effect, because of few cases with reduced BCVA in these studies.

Table 2. Associations with Peripapillary Retinal Nerve Fiber Layer Thickness for Each Individual Study

	Alienor (n=529)		Coimbra (n=618)		Montrachet (n=803)		LIFE (n=8351)	
	β (95% CI)	P	β (95% CI)	P	β (95% CI)	P	β (95% CI)	P
Age (per year)	-0.22 (-0.55 to 0.11)	0.12	-0.09 (-0.24 to 0.07)	0.28	-0.37 (-0.62 to -0.12)	0.004	-0.10 (-0.12 to -0.08)	<0.001
Female sex	3.98 (0.84–7.11)	0.01	2.78 (0.70–4.85)	0.01	3.85 (1.78–5.92)	<0.001	1.36 (0.90–1.82)	<0.001
BMI (per kg/m ²)	0.13 (-0.22 to 0.48)	0.46	-0.10 (-0.30 to 0.11)	0.37	0.33 (0.09–0.57)	0.006	0.08 (0.03–0.13)	0.002
SE (per diopter)	1.22 (0.50–1.94)	<0.001	1.15 (0.60–1.69)	<0.001	1.88 (1.44–2.31)	<0.001	N/A	N/A
IOP (per mmHg)	-0.71 (-1.32 to -0.10)	0.02	-0.52 (-0.84 to -0.19)	0.002	-0.31 (-0.60 to -0.03)	0.03	N/A	N/A
Visual impairment*	-6.42 (-12.47 to -0.37)	0.04	-0.15 (-4.64 to 4.34)	0.95	-0.49 (-4.46 to 3.48)	0.81	N/A	N/A
Former smoker	-0.47 (-3.74 to 2.81)	0.78	-0.57 (-3.67 to 2.53)	0.72	2.39 (0.25–4.53)	0.03	0.60 (0.06–1.14)	0.03
Current smoker	1.48 (-4.99 to 7.96)	0.65	1.51 (-5.74 to 8.77)	0.68	1.58 (-4.33 to 7.48)	0.60	1.43 (0.85–2.02)	<0.001
Hypertension	1.33 (-1.40 to 4.05)	0.34	-1.08 (-3.07 to 0.91)	0.29	-0.62 (-2.55 to 1.32)	0.53	-0.46 (-0.98 to 0.07)	0.09
Diabetes	2.11 (-2.30 to 6.52)	0.35	1.34 (-0.88 to 3.55)	0.24	-2.08 (-5.29 to 1.13)	0.21	-1.25 (-2.03 to -0.46)	0.002
Stroke	-3.53 (-14.05 to 6.99)	0.51	-2.85 (-7.60 to 1.91)	0.24	0.02 (-5.20 to 5.25)	0.99	-2.96 (4.56 to -1.36)	<0.001
Dementia	-5.11 (-12.06 to 1.84)	0.15	N/A	N/A	N/A	N/A	N/A	N/A
	Rotterdam I (n=1287)		Rotterdam II (n=1376)		Rotterdam III (n=2267)		Twins UK (n=853)	
	β (95% CI)	P	β (95% CI)	P	β (95% CI)	P	β (95% CI)	P
Age (per year)	-0.61 (-0.87 to -0.36)	<0.001	-0.91 (-1.08 to -0.73)	<0.001	-0.50 (-0.59 to -0.41)	<0.001	-0.24 (-0.29 to -0.18)	<0.001
Female sex	3.70 (1.23–6.16)	0.003	1.36 (-0.31 to 3.03)	0.11	0.49 (-0.50 to 1.48)	0.33	3.58 (-1.01 to 8.16)	0.13
BMI (per kg/m ²)	0.11 (-0.18 to 0.40)	0.46	0.00 (-0.002 to 0.002)	1.00	0.12 (0.00–0.24)	0.05	-0.07 (-0.19 to 0.05)	0.27
SE (per diopter)	1.09 (0.58–1.60)	<0.001	1.67 (1.32–2.02)	<0.001	1.29 (1.10–1.49)	<0.001	1.28 (1.02–1.55)	<0.001
IOP (per mmHg)	-0.49 (-0.84 to -0.14)	0.005	-0.65 (-0.91 to -0.39)	<0.001	-0.05 (-0.23 to 0.12)	0.56	-0.05 (-0.26 to 0.16)	0.62
Visual impairment*	-11.27 (-17.93 to -4.61)	<0.001	-7.68 (-13.80 to -1.55)	0.01	-9.56 (-14.87 to -4.24)	<0.001	N/A	N/A
Former smoker	2.60 (-0.05 to 5.25)	0.06	0.87 (-0.95 to 2.68)	0.36	-0.13 (-1.20 to 0.95)	0.82	N/A	N/A
Current smoker	2.96 (-1.48 to 7.40)	0.19	3.86 (0.94–6.78)	0.009	1.34 (-0.18 to 2.87)	0.08	N/A	N/A
Hypertension	2.08 (-1.71 to 5.86)	0.28	0.46 (-1.86 to 2.77)	0.70	-1.37 (-2.43 to -0.31)	0.01	N/A	N/A
Diabetes	-0.54 (-3.45 to 2.36)	0.71	-1.72 (-3.92 to 0.48)	0.12	0.40 (-1.30 to 2.10)	0.65	-4.29 (-8.34 to -0.24)	0.04
Stroke	1.25 (-2.83 to 5.32)	0.55	-2.06 (-5.67 to 1.55)	0.26	-1.22 (-4.19 to 1.76)	0.42	-1.51 (-5.49 to 2.48)	0.46
Dementia	-4.17 (-8.82 to 0.48)	0.08	-0.55 (-5.96 to 4.86)	0.84	-1.27 (-24.41 to 21.86)	0.91	N/A	N/A

BMI = body mass index; IOP = intraocular pressure; N/A = not available; SE = spherical equivalent.

Results from the multivariable regression models.

*Visual impairment as defined by the World Health Organization (<0.3 decimal BCVA).

Table 3. Meta-Analyzed Associations with Peripapillary Retinal Nerve Fiber Layer Thickness

	All Participants			Excluding Known Glaucoma		
	β (95% CI)	P	I ²	β (95% CI)	P	I ²
Age (per year)	-0.38 (-0.57 to -0.18)	<0.001	97%	-0.35 (-0.60 to -0.10)	0.006	97%
Female sex	2.17 (1.15–3.20)	<0.001	69%	1.79 (0.93–2.65)	<0.001	59%
BMI (per kg/m ²)	0.06 (-0.02 to 0.14)	0.15	54%	0.09 (0.00–0.18)	0.05	53%
SE (per diopter)	1.39 (1.19–1.59)	<0.001	49%	1.36 (1.16–1.57)	<0.001	40%
IOP (per mmHg)	-0.36 (-0.56 to -0.15)	<0.001	74%	-0.42 (-0.65 to -0.20)	<0.001	71%
Visual impairment*	-5.50 (-9.37 to -1.64)	0.005	69%	-4.75 (-9.12 to -0.38)	0.03	77%
Former smoker	0.58 (0.14–1.02)	0.009	0%	0.79 (-0.01 to 1.60)	0.05	43%
Current smoker	1.53 (1.00–2.06)	<0.001	0%	1.49 (0.97–2.02)	<0.001	0%
Hypertension	-0.54 (-1.01 to -0.07)	0.03	4%	-0.62 (-1.11 to -0.13)	0.01	7%
Diabetes	-0.69 (-1.69 to 0.31)	0.18	40%	-0.33 (-1.32 to 0.67)	0.52	40%
Stroke	-1.94 (-3.17 to -0.72)	0.002	7%	-2.06 (-3.27 to -0.84)	<0.001	2%
Dementia	-3.11 (-6.22 to 0.01)	0.05	0%	-2.66 (-5.86 to 0.55)	0.10	0%

BMI = body mass index; CI = confidence interval; IOP = intraocular pressure; SE = spherical equivalent.

All participants: results of the meta-analysis of the multivariable regression models including all participants (n=16 084).

Excluding known glaucoma: results of the meta-analysis of the multivariable regression models excluding the 619 patients with known glaucoma (n=14 695, without TwinsUK Study data, because no data on glaucoma were available); I² = heterogeneity of covariate in the meta-analysis.

*Visual impairment as defined by the World Health Organization (<0.3 decimal BCVA).

Previous studies reported contradictory results on the impact of hypertension and blood pressure on pRNFLT.^{9,23,24} Our results show reduced pRNFLT in hypertensive patients, but no association of pRNFLT with actual systolic blood pressure. However, blood pressure measurements are known to vary with method, and associations with systolic blood pressure may have been masked by any use of antihypertensive medication. In contrast to hypertension, most studies investigating the effect of diabetes on pRNFLT report diabetic patients to have thinner pRNFLT.^{25,26} This is not in agreement with our results that do not show an association of reduced pRNFLT in diabetic patients. Nevertheless, we hypothesize that microvascular pathology and ischemia due to hypertension or diabetes may be a cause for reduced pRNFLT, as has been suggested previously.²⁵

Both former and current smoking were associated with thicker pRNFLT in our meta-analysis, even in several sensitivity analyses including correction for educational level. This association does not seem biologically plausible given the observed pRNFLT decrease in metabolic diseases. Potential biologic explanations could be reduced axonal flow or axonal swelling in the course of axonal degeneration because of intake of neurotoxins and cytotoxins from cigarette smoke. However, our results are in contrast with findings of earlier studies,^{27,28} which reported reduced pRNFLT in smokers. Suggested mechanisms leading to decreased pRNFLT were toxic damage through free radicals, increased IOP, and reduced perfusion.^{27–29} We controlled for IOP, hypertension, and diabetes, which all may influence perfusion. Therefore, it is unclear what might explain this association. Current smokers were on average younger in our participating studies compared with never and former smokers. Although we controlled for age in our models, we cannot entirely rule out residual confounding. Also, the European Eye Epidemiology (E3) studies are not representative studies of European populations, and

smoking percentages do not reflect actual percentages. There was heterogeneity between studies considering smoking prevalence and oppositional effects of former smoking in some studies. After excluding the LIFE Study, which was dominantly weighted in the smoking meta-analysis, the Rotterdam Study III showed to be weighted strongest for current smoking. When also excluding the Rotterdam Study III, the impact of smoking is weakened but holds true. Still, the associations seem to be particularly driven by the large studies. This is also underlined by increasing heterogeneity for former and current smoking in the meta-analysis after excluding the LIFE Study. Moreover, there is no information on the time interval between cessation of smoking and OCT imaging for the former smokers, which also may have an impact. Further studies are needed to confirm or refute our observation, which may be a chance finding.

Past studies have reported patients with stroke to have thinner pRNFLT, which was hypothesized to be caused by transneuronal retrograde degeneration.^{30,31} Our data confirm the association of stroke and decreased pRNFLT. In patients with dementia, we found a trend of reduced pRNFLT. Again, this is in accordance with various previous studies, which report patients with dementia to have reduced pRNFLT.^{4,32} Thus far, the underlying mechanisms remain unclear. Loss of peripapillary RNFL is a hallmark of glaucoma, and longitudinal pRNFLT evaluation is a crucial part of glaucoma management. In our meta-analysis, all associations persisted after excluding patients with known glaucoma except for former smoking. This indicates that the detected determinants are independent of the presence of glaucoma.

As described previously, structural decline of pRNFLT occurs before functional loss in perimetry in patients with glaucoma. An earlier study reported the difference in pRNFLT between glaucomatous and healthy eyes 8 years

Figure 1. A, Forest plots of meta-analyzed associations with peripapillary retinal nerve fiber layer thickness (pRNFLT) from multivariable regression models (age, sex, spherical equivalent [SE], intraocular pressure [IOP], and visual impairment). B, Forest plots of meta-analyzed associations with pRNFLT from multivariable regression models (smoking, hypertension, stroke, and dementia). The beta-coefficients (95% CI) show the influence of each parameter on pRNFLT within the respective study, and the percentage represents the mathematically determined weighting of each study within the meta-analysis.

before the onset of visual field impairment to be approximately 5 μm .³³ This is in the range of some associations found in our study and underlines the potential impact on the interpretation of pRNFLT. Our results have 2 main clinical implications. First, the normative databases built into the devices should reflect our results when presenting normal values for pRNFLT. Also, the presence of vascular disease including a history of stroke should be considered when defining normative datasets or when clinically evaluating pRNFLT. As discussed earlier, the magnitude of impact of the respective determinants may have clinical relevance, especially in the presence of more than 1 factor reducing pRNFLT. Second, in those with glaucoma or other patients followed up with pRNFLT measurements,

an incident stroke or dementia may cause a decrease in pRNFLT, which would not primarily be due to glaucoma or other ocular disease progression. For example, this may simulate an aggravation of glaucoma and needs to be considered by the clinician when tailoring the glaucoma management.

The strengths of this study consist of the large pooled sample combining data of 8 studies from 5 European countries. To our knowledge, this study represents one of the largest European studies on determinants of pRNFLT thus far. As mentioned, previous population studies reporting data on associations with pRNFLT were conducted in mostly Asian populations, and the results cannot directly be transferred to European individuals. The

associations of this study were assessed in meta-analyses of all participating populations; thus, they are not limited to 1 single population only. This reduces the possibility that an association was solely due to chance within 1 population and increases generalizability. However, several limitations of our study need to be considered. The use of different OCT devices between studies may have increased variability and prohibited direct pooling of pRNFLT data. To overcome this lack of direct comparability, we performed the analysis separately within studies and then pooled studies' effect estimates using random-effect meta-analysis. Furthermore, we found no interactions between type of device and any predictor variable in additional sensitivity analyses in the Rotterdam Study II and III, which had a device upgrade within the course of the study. However, residual influence of different OCT devices cannot be entirely excluded. As expected when combining different large-scale population studies, we observed between-study heterogeneity for the independent variables and their influence on pRNFLT. The degree of heterogeneity of the respective covariates was assessed using the I² and statistics, and ranged from 0% to 97% (Table 3). As described, this heterogeneity between studies was addressed by using random effect meta-analysis.¹⁷ In accordance with previous literature, the relationship between pRNFLT and age was linear in our sample. Having no data for children and young adults, we do not know whether the relationship between pRNFLT and age is strictly linear throughout life but would assume so on the basis of our data. Thus, we investigated associations using multivariable linear regression modeling, and any nonlinear relationships may have been underrepresented. Quality control was performed within each study differently (Table S2, available at www.aaojournal.org). Some studies performed manual (re)-segmentation and excluded OCT images below a certain scan quality and scans with artifacts, whereas others included all scans with sufficient quality as evaluated by the performing technician. In the sensitivity analysis, we excluded participants with an image quality value <45 (as recommended by the manufacturer) in the Rotterdam Studies I–III. We found no relevant changes of direction in any association, but the CIs became broader because of a reduced sample size (Table S3, available at www.aaojournal.org). Thus, although the lack of centralized quality control is a limitation to our analyses, the impact of poor-quality scans seems to be low as indicated by our supplemental sensitivity analyses. Within each study, the number of participants in whom OCT imaging could not be performed or in whom the images were of low quality and thus unusable is only a small proportion

(Table S2, available at www.aaojournal.org). For example, in the Rotterdam Study I–III the number of participants with no or insufficient OCT data was 10%, 6%, and 15%, respectively. These subjects were older and more likely to have stroke (Rotterdam Study I), dementia (Rotterdam Study II and III), and hypertension (Rotterdam Study III) than the included participants. This indicates that our associations may be underestimations of the true effect. Several independent variables were not available in some studies. Therefore, not all multivariable models could be corrected for all variables. However, no relevant differences of associations were detectable when comparing studies with and without any missing data. Thus, the absence of certain variables in some studies did not relevantly alter the associations of the available data. Methods of assessments varied between our studies. This concerns the BCVA, which was sometimes measured subjectively and sometimes by autor-etractor. In addition, information on diseases was assessed differently. Although glaucoma was defined on the basis of optic disc evaluation and perimetry in the Alienor Study and Rotterdam Study I–III, it was self-reported in the LIFE Study. Furthermore, we did not distinguish between the various types of dementia, which may have a different impact on pRNFLT. These differences contribute again to larger heterogeneity, and the relation between self-reported diseases and pRNFLT may have been estimated with less precision. Last, our data were cross-sectional only, and causal deductions from the detected associations are limited and further longitudinal studies are needed.

In conclusion, the current analyses identified important additional determinants of pRNFLT, which should be considered when assessing pRNFLT both clinically and in epidemiologic research. The magnitude of changes in pRNFLT by determinant is likely clinically relevant, and the biology of pRNFLT thinning is complex, with mechanical pressure, microvascular ischemia, and neuronal degeneration being implied. This is reflected in the complexity of factors that influence pRNFLT and thus needs to be considered. In particular, the associations with systemic vascular and neurovascular diseases merit further research.

Acknowledgments

The authors acknowledge the contribution of the following: Alberta A. H. J. Thiadens (Rotterdam), Nomdo M. Jansonius (Groningen/Rotterdam), and Paulus de Jong (Rotterdam). The authors thank Dr. Matthias Nuechter (LIFE) for his enthusiastic assistance to this collaborative research, Dr. Kerstin Wirkner (LIFE) and her team for data acquisition, and Dr. Toralf Kirsten (LIFE) for IT structure and overall support. Furthermore, the authors thank Verena Brendler (LIFE) and Yvonne Dietz (LIFE) for data management.

Members of the European Eye Epidemiology (E3) Consortium:

Last Name	First Name	Institution	City	Country
Acar	Niyazi	Inra-University of Burgundy	Dijon	France
Anastosopoulos	Eleftherios	University of Thessaloniki	Thessaloniki	Greece
Azuara-Blanco	Augusto	Queen's University	Belfast	UK
Berendschot	Tos	University Eye Clinic Maastricht	Maastricht	Netherlands
Berendschot	Tos	University of Maastricht	Maastricht	Netherlands
Bergen	Arthur	Netherlands Institute for Neurosciences-KNAW	Amsterdam	Netherlands
Bertelsen	Geir	University of Tromso	Tromso	Norway
Binquet	Christine	University Hospital of Dijon	Dijon	France
Bird	Alan	Moorfield's Eye Hospital	London	UK
Bobak	Martin	Lithuanian University of Health Sciences	Kaunas	Lithuania
Bøgelund Larsen	Morten	University of Southern Denmark/Odense University Hospital	Odense	Denmark
Boon	Camiel	Leiden University Medical Center	Leiden	Netherlands
Bourne	Rupert	University of Rusk	Cambridge	England
Brétilon	Lionel	Inra-University of Burgundy	Dijon	France
Broe	Rebecca	University of Southern Denmark	Odense	Denmark
Bron	Alain	University Hospital of Dijon	Dijon	France
Buitendijk	Gabrielle	Erasmus Medical Center	Rotterdam	Netherlands
Cachulo	Maria Luz	AIBILI/CHUC	Coimbra	Portugal
Capuano	Vittorio	University Hospital of Créteil	Créteil	France
Carrière	Isabelle	Inserm U1061	Montpellier	France
Chakravarthy	Usha	Queen's University	Belfast	UK
Chan	Michelle	UCL Institute of Ophthalmology	London	UK
Chang	Petrus	University of Bonn	Bonn	Germany
Colijn	Johanna	Erasmus Medical Center	Rotterdam	Netherlands
Cougnard-Grégoire	Audrey	Bordeaux Population Health Research Center UMR1219	Bordeaux	France
Cree	Angela	University of Southampton	Southampton	UK
Creuzot-Garcher	Catherine	University Hospital of Dijon	Dijon	France
Cumberland	Phillippa	UCL Institute of Child Health	London	UK
Cunha-Vaz	José	AIBILI/CHUC	Coimbra	Portugal
Daien	Vincent	Inserm U1061	Montpellier	France
De Jong	Eiko	Radboud University	Nijmegen	Netherlands
Deak	Gabor	Medical University of Vienna	Vienna	Austria
Delcourt	Cécile	Bordeaux Population Health Research Center UMR1219	Bordeaux	France
Delyfer	Marie-Noëlle	Bordeaux Population Health Research Center UMR1219	Bordeaux	France
den Hollander	Anneke	Radboud University	Nijmegen	Netherlands
Dietzel	Martha	University of Muenster	Muenster	Germany
Erke	Maja Gran	University of Tromso	Tromso	Norway
Faria	Pedro	AIBILI/CHUC	Coimbra	Portugal
Farinha	Claudia	AIBILI/CHUC	Coimbra	Portugal
Fausser	Sascha	University Eye Hospital	Cologne	Germany
Finger	Robert	University of Bonn	Bonn	Germany
Fletcher	Astrid	London School of Hygiene and Tropical Medicine	London	UK
Foster	Paul	UCL Institute of Ophthalmology	London	UK
Founti	Panayiota	University of Thessaloniki	Thessaloniki	Greece
Gorgels	Theo	Netherlands Institute for Neurosciences-KNAW	Amsterdam	Netherlands
Grauslund	Jakob	University of Southern Denmark	Odense	Denmark
Grus	Franz	University Medical Center Mainz	Mainz	Germany
Hammond	Christopher	King's College	London	UK
Hense	Hans-Werner	University of Muenster	Muenster	Germany
Hermann	Manuel	University Eye Hospital	Cologne	Germany
Hoehn	René	University Medical Center	Mainz	Germany
Hogg	Ruth	Queen's University	Belfast	UK
Holz	Frank	University of Bonn	Bonn	Germany
Hoyng	Carel	Radboud University	Nijmegen	Netherlands
Jansonius	Nomdo	Erasmus Medical Center	Rotterdam	Netherlands
Janssen	Sarah	Netherlands Institute for Neurosciences-KNAW	Amsterdam	Netherlands
Kersten	Eveline	Radboud University	Nijmegen	Netherlands
Khawaja	Anthony	NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology	London	UK
Klaver	Caroline	Erasmus Medical Center	Rotterdam	Netherlands
Korobelnik	Jean-François	Bordeaux Population Health Research Center UMR1219	Bordeaux	France
Lamparter	Julia	University Medical Center Mainz	Mainz	Germany
Le Goff	Mélanie	Bordeaux Population Health Research Center UMR1219	Bordeaux	France

(Continued)

Members of the European Eye Epidemiology (E3) Consortium: (Continued.)

Last Name	First Name	Institution	City	Country
Lechanteur	Yara	Radboud University	Nijmegen	Netherlands
Lehtimäki	Terho	Fimlab Laboratories and School of Medicine, University of Tampere	Tampere	Finland
Leung	Irene	Moorfield's Eye Hospital	London	UK
Lotery	Andrew	University of Southampton	Southampton	UK
Mauschitz	Matthias	University of Bonn	Bonn	Germany
Meester	Magda	Erasmus Medical Center	Rotterdam	Netherlands
Merle	Bénédicte	Bordeaux Population Health Research Center UMR1219	Bordeaux	France
Meyer zu Westrup	Verena	University of Muenster	Muenster	Germany
Midena	Edoardo	University of Padova	Padova	Italy
Miotto	Stefania	University of Padova	Padova	Italy
Mirshahi	Alireza	Dardenne Eye Hospital	Bonn	Germany
Mohan-Saïd	Sadek	Institut de la Vision	Paris	France
Mueller	Michael	Pirkanmaa Hospital District	Tampere	Finland
Muldrew	Alyson	Queen's University	Belfast	UK
Murta	Joaquim	AIBILI/CHUC	Coimbra	Portugal
Nickels	Stefan	University Medical Center	Mainz	Germany
Nunes	Sandrina	AIBILI/CHUC	Coimbra	Portugal
Owen	Christopher	University of London	London	UK
Peto	Tunde	Queen's University	Belfast	UK
Pfeiffer	Norbert	University Medical Center	Mainz	Germany
Piermarocchi	Stefano	University of Padova	Padova	Italy
Prokofyeva	Elena	Scientific Institute of Public Health (WIV-ISP)	Brussels	Belgium
Rahi	Jugnoo	UCL Institute of Ophthalmology	London	UK
Raitakari	Olli	Turku University Hospital, University of Turku	Turku	Finland
Rauscher	Franziska	Leipzig University Hospital	Leipzig	Germany
Ribeiro	Luisa	AIBILI/CHUC	Coimbra	Portugal
Rougier	Marie-Bénédicte	Bordeaux Population Health Research Center UMR1219	Bordeaux	France
Rudnicka	Alicja	University of London	London	UK
Sahel	José	Institut de la Vision	Paris	France
Salonikiou	Aggeliki	University of Thessaloniki	Thessaloniki	Greece
Sanchez	Clarisa	Radboud University	Nijmegen	Netherlands
Schmitz-Valckenberg	Steffen	University of Bonn	Bonn	Germany
Schuster	Alexander	University Medical Center	Mainz	Germany
Schweitzer	Cédric	Bordeaux Population Health Research Center UMR1219	Bordeaux	France
Segato	Tatiana	University of Padova	Padova	Italy
Shehata	Jasmin	Medical University of Vienna	Vienna	Austria
Silva	Rufino	AIBILI/CHUC	Coimbra	Portugal
Silvestri	Giuliana	Queen's University	Belfast	UK
Simader	Christian	Medical University of Vienna	Vienna	Austria
Souied	Eric	University Hospital of Créteil	Créteil	France
Speckauskas	Martynas	Lithuanian University of Health Sciences	Kaunas	Lithuania
Springelkamp	Henriet	Erasmus Medical Center	Rotterdam	Netherlands
Tapp	Robyn	Pirkanmaa Hospital District	Tampere	Finland
Topouzis	Fotis	University of Thessaloniki	Thessaloniki	Greece
van Leeuwen	Elisa	Erasmus Medical Center	Rotterdam	Netherlands
Verhoeven	Virginie	Erasmus Medical Center	Rotterdam	Netherlands
Verzijden	Timo	Erasmus Medical Center	Rotterdam	Netherlands
Von Hanno	Therese	University of Tromsø	Tromsø	Norway
Wiedemann	Peter	Leipzig University Hospital	Leipzig	Germany
Williams	Katie	King's College London	London	UK
Wolfram	Christian	University Medical Center	Mainz	Germany
Yip	Jennifer	UCL Institute of Ophthalmology	London	UK
Zerbib	Jennyfer	University Hospital of Créteil	Créteil	France

References

1. Mwanza J-C, Oakley JD, Budenz DL, Anderson DR. Ability of cirrus HD-OCT optic nerve head parameters to discriminate normal from glaucomatous eyes. *Ophthalmology*. 2011;118:241.
2. Gardiner SK, Fortune B, Demirel S. Localized changes in retinal nerve fiber layer thickness as a predictor of localized functional change in glaucoma. *Am J Ophthalmol*. 2016;170:75–82.
3. Marziani E, Pomati S, Ramolfo P, et al. Evaluation of retinal nerve fiber layer and ganglion cell layer thickness in Alzheimer's disease using spectral-domain optical coherence tomography. *Invest Ophthalmol Vis Sci*. 2013;54:5953–5958.
4. Jones-Odeh E, Hammond CJ. How strong is the relationship between glaucoma, the retinal nerve fibre layer, and neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis? *Eye (Lond)*. 2015;29:1270–1284.
5. Rougier M-B, Korobelnik J-F, Malet F, et al. Retinal nerve fibre layer thickness measured with SD-OCT in a

- population-based study of French elderly subjects: the Alienor study. *Acta Ophthalmol.* 2015;93:539–545.
6. Zhu B-D, Li S-M, Li H, et al. Retinal nerve fiber layer thickness in a population of 12-year-old children in central China measured by iVue-100 spectral-domain optical coherence tomography: the Anyang Childhood Eye Study. *Invest Ophthalmol Vis Sci.* 2013;54:8104–8111.
 7. Chauhan BC, Danthurebandara VM, Sharpe GP, et al. Bruch's membrane opening minimum rim width and retinal nerve fiber layer thickness in a normal white population: a multicenter study. *Ophthalmology.* 2015;122:1786–1794.
 8. Leung CKS, Yu M, Weinreb RN, et al. Retinal nerve fiber layer imaging with spectral-domain optical coherence tomography: a prospective analysis of age-related loss. *Ophthalmology.* 2012;119:731–737.
 9. Schuster AK-G, Fischer JE, Vossmerbaeumer C, Vossmerbaeumer U. Determinants of peripapillary retinal nerve fiber layer thickness regarding ocular and systemic parameters—the MIPH Eye&Health Study. *Graefes Arch Clin Exp Ophthalmol.* 2016;254:2011–2016.
 10. Yamashita T, Sakamoto T, Yoshihara N, et al. Correlations between retinal nerve fiber layer thickness and axial length, peripapillary retinal tilt, optic disc size, and retinal artery position in healthy eyes. *J Glaucoma.* 2017;26:34–40.
 11. Cheung CY, Chen D, Wong TY, et al. Determinants of quantitative optic nerve measurements using spectral domain optical coherence tomography in a population-based sample of non-glaucomatous subjects. *Invest Ophthalmol Vis Sci.* 2011;52:9629–9635.
 12. Chen L, Huang J, Zou H, et al. Retinal nerve fiber layer thickness in normal Chinese students aged 6 to 17 years. *Invest Ophthalmol Vis Sci.* 2013;54:7990–7997.
 13. Kang M-T, Li S-M, Li H, et al. Peripapillary retinal nerve fibre layer thickness and its association with refractive error in Chinese children: the Anyang Childhood Eye Study. *Clin Experiment Ophthalmol.* 2016;44:701–709.
 14. Zhao L, Wang Y, Chen CX, et al. Retinal nerve fibre layer thickness measured by Spectralis spectral-domain optical coherence tomography: The Beijing Eye Study. *Acta Ophthalmol.* 2014;92:e35–e41.
 15. Delcourt C, Korobelnik J-F, Buitendijk GHS, et al. Ophthalmic epidemiology in Europe: the “European Eye Epidemiology” (E3) consortium. *Eur J Epidemiol.* 2016;31:197–210.
 16. Chauvenet W. *A Manual of Spherical and Practical Astronomy*. 5th ed. Philadelphia: Lippincott; 1906:469–566.
 17. Khawaja AP, Springelkamp H, Creuzot-Garcher C, et al. Associations with intraocular pressure across Europe: The European Eye Epidemiology (E3) Consortium. *Eur J Epidemiol.* 2016;31:1101–1111.
 18. Nagai-Kusuhara A, Nakamura M, Fujioka M, et al. Association of retinal nerve fibre layer thickness measured by confocal scanning laser ophthalmoscopy and optical coherence tomography with disc size and axial length. *Br J Ophthalmol.* 2008;92:186–190.
 19. Budenz DL, Anderson DR, Varma R, et al. Determinants of normal retinal nerve fiber layer thickness measured by Stratus OCT. *Ophthalmology.* 2007;114:1046–1052.
 20. Mwanza J-C, Durbin MK, Budenz DL, et al. Profile and predictors of normal ganglion cell-inner plexiform layer thickness measured with frequency-domain optical coherence tomography. *Invest Ophthalmol Vis Sci.* 2011;52:7872–7879.
 21. Kang SH, Hong SW, Im SK, et al. Effect of myopia on the thickness of the retinal nerve fiber layer measured by Cirrus HD optical coherence tomography. *Invest Ophthalmol Vis Sci.* 2010;51:4075–4083.
 22. Higashide T, Ohkubo S, Hangai M, et al. Influence of clinical factors and magnification correction on normal thickness profiles of macular retinal layers using optical coherence tomography. *PLoS One.* 2016;11, e0147782.
 23. Sahin OZ, Sahin SB, Ayaz T, et al. The impact of hypertension on retinal nerve fiber layer thickness and its association with carotid intima media thickness. *Blood Press.* 2015;24:178–184.
 24. Topouzis F, Coleman AL, Harris A, et al. Association of blood pressure status with the optic disk structure in non-glaucoma subjects: the Thessaloniki eye study. *Am J Ophthalmol.* 2006;142:60–67.
 25. Jeon SJ, Kwon J-W, La TY, et al. Characteristics of retinal nerve fiber layer defect in nonglaucomatous eyes with type II diabetes. *Invest Ophthalmol Vis Sci.* 2016;57:4008–4015.
 26. Carpineto P, Toto L, Aloia R, et al. Neuroretinal alterations in the early stages of diabetic retinopathy in patients with type 2 diabetes mellitus. *Eye (Lond).* 2016;30:673–679.
 27. El-Shazly AAE-F, Farweez YAT, Elewa LS, et al. Effect of active and passive smoking on retinal nerve fibre layer and ganglion cell complex. *J Ophthalmol.* 2017;2017:6354025.
 28. Dervişoğulları MS, Totan Y, Tenlik A, et al. Effect of smoking on retina nerve fiber layer and ganglion cell-inner plexiform layer complex. *Cutan Ocul Toxicol.* 2015;34:282–285.
 29. Yoshida M, Take S, Ishikawa M, et al. Association of smoking with intraocular pressure in middle-aged and older Japanese residents. *Environ Health Prev Med.* 2014;19:100–107.
 30. Park H-YL, Park YG, Cho A-H, Park CK. Transneuronal retrograde degeneration of the retinal ganglion cells in patients with cerebral infarction. *Ophthalmology.* 2013;120:1292–1299.
 31. Anjos R, Vieira L, Costa L, et al. Macular ganglion cell layer and peripapillary retinal nerve fibre layer thickness in patients with unilateral posterior cerebral artery ischaemic lesion: an optical coherence tomography study. *Neuroophthalmology.* 2016;40:8–15.
 32. He X-F, Liu Y-T, Peng C, et al. Optical coherence tomography assessed retinal nerve fiber layer thickness in patients with Alzheimer's disease: a meta-analysis. *Int J Ophthalmol.* 2012;5:401–405.
 33. Kuang TM, Zhang C, Zangwill LM, et al. Estimating lead time gained by optical coherence tomography in detecting glaucoma before development of visual field defects. *Ophthalmology.* 2015;122:2002–2009.

Footnotes and Financial Disclosures

Originally received: November 13, 2017.

Final revision: March 9, 2018.

Accepted: March 15, 2018.

Available online: April 28, 2018.

Manuscript no. 2017-2605.

¹ Population Health Sciences, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.

² Department of Ophthalmology, University of Bonn, Bonn, Germany.

³ Department of Ophthalmology, Erasmus MC, Rotterdam, The Netherlands.

⁴ Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands.

⁵ Leipzig Research Centre for Civilization Diseases, Leipzig University, Leipzig, Germany.

⁶ Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts.

⁷ Institute for Medical Informatics, Statistics and Epidemiology, Leipzig University, Leipzig, Germany.

⁸ Section of Academic Ophthalmology, School of Life Course Sciences, FoLSM, King's College London, London, United Kingdom.

⁹ Department of Ophthalmology, University Hospital Dijon, Dijon, France.

¹⁰ Eye and Nutrition Research Group, University of Bourgogne Franche Comté, Dijon, France.

¹¹ Department of Ophthalmology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.

¹² Faculty of Medicine, University of Coimbra, Institute for Biomedical Imaging and Life Sciences, Coimbra, Portugal.

¹³ Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal.

¹⁴ University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Team LEHA, Bordeaux, France.

¹⁵ Institute for Medical Biometry, Informatics and Epidemiology (IMBIE), Faculty of Medicine, University of Bonn, Bonn, Germany.

Financial Disclosure(s):

The author(s) have made the following disclosure(s): A.M.B.: Personal fees — Allergan, Bausch & Lomb, Théa, Carl Zeiss Meditec; Grants — Horus, outside the submitted work.

C.C.-G.: Grants and personal fees: Allergan; Personal fees — Bayer; Personal fees and other — Novartis; Grants — Horus; Grants and personal fees — Thea, outside the submitted work.

C.D.: Consultant — Allergan, Bausch & Lomb, Laboratoires Théa, Novartis, Roche, outside the submitted work.

F.G.H.: Fees — Heidelberg Engineering, Optos, Zeiss, Genentech, Acucela, Bayer Healthcare, Novartis, outside the submitted work.

R.P.F.: Fees — Novartis, Bayer, AbbVie, Opthea, Novartis, Retina Implant, Santen, outside the submitted work.

R.S.: Member of the Advisory Board for Novartis, Bayer, Allergan, Alimera, Alcon, Thea.

T.E.: Grant Support — BrightFocus Foundation, Lions Foundation, Grimshaw-Gudewicz Foundation, Research to Prevent Blindness, and National Eye Institute Core Grant P30EY003790.

C.C.W.K.: Consulting fee or honorarium — Thea Pharma, Bayer, Novartis; Consultant — Thea Pharma, Bayer; Lecture fees — Bayer.

The Alienor Study was supported by Laboratoires Théa (Clermont-Ferrand, France); University of Bordeaux (Bordeaux, France); Fondation Voir et Entendre (Paris, France); and Caisse Nationale de Solidarité pour l'Autonomie CNSA (CNSA). The Coimbra Study is an Investigator Initiated Study financially supported by Novartis Pharma AG. This publication is supported by the Leipzig Research Centre for Civilization Diseases (LIFE), an organizational unit affiliated to the Medical Faculty of Leipzig University. LIFE is funded by means of the European Union, by the European Regional Development Fund and by funds of the Free State of Saxony within the framework of the excellence initiative (project nos: 713-241202, 713-241202, 14505/2470, 14575/2470).

Montrachet Study: Funding was provided by an Inter-regional grant (PHRC) and the Regional Council of Burgundy. Funded by INRA, CNRS, Université de Bourgogne, Regional Council of Burgundy France (PARI Agrale 1), FEDER (European Funding for Regional Economic Development), and French Government grant managed by the French National Research Agency (ANR) as part of the "Investissements d'Avenir" program (reference ANR-11-LABX-0021-

01-LipSTIC Labex). The Rotterdam Study is funded by Erasmus MC and Erasmus University, Rotterdam, Netherlands; Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. SENSE-COG consortium has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 668648. Stichting Lijf en Leven, Krimpen aan de Lek; MD Fonds, Utrecht; Rotterdamse Vereniging Blindenbelangen, Rotterdam; Stichting Oogfonds Nederland, Utrecht; Blindenpenning, Amsterdam; Blindenhulp, The Hague; Algemene Nederlandse Vereniging ter Voorkoming van Blindheid (ANVVB), Doorn; Landelijke Stichting voor Blinden en Slechthzienden, Utrecht; Swart van Essen, Rotterdam; Stichting Winckel-Sweep, Utrecht; Henkes Stichting, Rotterdam; Laméris Ootech BV, Nieuwegein; Medical Workshop, de Meern; Topcon Europe BV, Capelle aan de IJssel, all in the Netherlands, and Heidelberg Engineering, Dossenheim, Germany. Also supported by the NWO Graduate Programme 2010 BOO (022.002.023; HS), the National Institute of Health (Bethesda, MD) Grants R01 EY019112 and R01 EY018853, Veterans Administration Grant I01 CX000119, and the Arnold and Mabel Beckman Initiative for Macular Research. TwinsUK phenotyping was funded by the International Glaucoma Association (2013 research award) and the Wellcome Trust. Supported by the National Institute for Health Research—funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. R.P.F.'s research group receives funding from the Else Kröner-Fresenius-Stiftung (GSO/EKFS 16) and the Jackstädt Stiftung.

HUMAN SUBJECTS: Human subjects, human-derived materials, or human medical records were part of this study protocol. All studies adhered to the tenets of the Declaration of Helsinki and had local ethical committee approval. All participants gave written informed consent.

No animal subjects were used in this study.

Author Contributions:

Conception and design: Mauschitz, Delcourt, Holz, Klaver, Breteler, Finger
Data collection: Bonnemaier, Rauscher, Elze, Engel, Loeffler, Colijn, Ikram, Vingerling, Williams, Hammond, Creuzot-Garcher, Bron, Silva, Nunes, Delcourt, Cougnard-Grégoire, Klaver

Analysis and interpretation: Mauschitz, Bonnemaier, Diers, Rauscher, Cougnard-Grégoire, Klaver, Breteler, Finger

Obtained funding: N/A

Overall responsibility: Mauschitz, Bonnemaier, Klaver, Finger

Abbreviations and Acronyms:

AL = axial length; **BCVA** = best-corrected visual acuity; **BMI** = body mass index; **CI** = confidence interval; **IOP** = intraocular pressure; **prNFLT** = peripapillary retinal nerve fiber layer thickness; **SE** = spherical equivalent.

Correspondence:

Robert P. Finger, MD, PhD, Department of Ophthalmology, University of Bonn, Germany, Ernst-Abbe-Straße 2, 53127 Bonn, Germany. E-mail: robert.finger@ukbonn.de.